A standard seven day pill organizer, from NIAID's public health image library
NIAIDCC BY 2.0
Illustrative. A generic weekly pill organizer, not VK2735 or any specific medication.
You May Not Need a Weekly GLP1 Shot Forever, Viking's New Trial Suggests
Most of the conversation around GLP1 and GIP drugs has been about how much weight they take off. Viking Therapeutics' newest data asks a different question: once the weight is off, how rarely can someone dose and still keep it there. The early answer is more encouraging than you might expect.
- Viking Therapeutics announced Phase 2 topline results on September 22, 2026 for VK2735, its dual GLP1 and GIP drug.
- A 21 week induction phase produced 16 to 19% weight loss. Switching to dosing every other week then held onto up to 97% of that loss, and switching to once a month held onto up to 90%.
- The group that stopped active dosing entirely kept only 61% of the weight they had lost.
- This is company reported topline data from a real randomized, placebo controlled trial, not yet peer reviewed or independently replicated.
The trial and what it found
On September 22, 2026, Viking announced Phase 2 results from its VK2735 maintenance study, called VK2735 102. Roughly 180 adults with obesity went through a 21 week induction phase of weekly injections, escalating up to final doses of 15.0 to 22.5 milligrams. By week 21, participants had lost a mean 16 to 19% of body weight, compared with roughly 0% on placebo, and Viking says the curve had not plateaued.
Participants were then re randomized into a 12 week maintenance phase testing different dosing schedules. Dosing every other week, at 5.0 to 10.0 milligrams, held onto up to 97% of the weight already lost. Dosing once a month, at 10.0 to 22.5 milligrams, held onto up to 90%. The group that stopped active dosing and moved to placebo maintenance kept only 61%. A separate group that kept dosing weekly kept losing weight, reaching 21.7% cumulative loss by week 33.
Why dosing frequency is the actually new part
Every major GLP1 and GIP drug on the market or in late stage trials is a weekly injection, and the real world friction of a weekly shot, needle fatigue, cost, refill logistics, comes up constantly in how people actually use these drugs. If a monthly injection can hold onto roughly nine tenths of the weight already lost, that is a genuinely different adherence proposition than what is currently available, even before anyone changes the amount of weight lost in the first place. Viking has not yet tested oral maintenance dosing, which it says is planned for a future stage of the program.
Honest caveat
This is a single company reported Phase 2 topline readout. It has not been published in a peer reviewed journal, has not been independently replicated, and Viking has an obvious financial interest in a favorable result. The maintenance phase lasted only 12 weeks, the roughly 180 participants were split across seven or more dosing arms, so individual arm sizes are modest, and there is no data yet on whether these effects hold beyond 33 weeks total. Phase 3 obesity trials are ongoing separately and could turn out differently.
What this means for you
If you are already on a GLP1 or GIP drug, or considering one, this is not yet a reason to ask your prescriber about switching to monthly dosing. VK2735 is not an approved drug, and this maintenance schedule has not been tested outside a company sponsored Phase 2 trial. What it does mean is that dosing frequency is becoming a real, separate axis to watch in this drug class alongside weight loss percentage, one worth tracking as more companies report their own maintenance data over the next year or two.
Primary sources
Common questions
What is VK2735 and how is it different from Ozempic or Zepbound?
VK2735 is Viking Therapeutics' injectable drug that activates both the GLP1 and GIP receptors, the same dual mechanism as Eli Lilly's tirzepatide (Zepbound, Mounjaro), rather than the single GLP1 mechanism behind semaglutide (Ozempic, Wegovy). It is still in Phase 2 testing and is not an approved or available drug.
Does this mean GLP1 drugs will soon be a once a month shot?
Not yet, and not for everyone. This maintenance dosing data only covers a 12 week window after an initial 21 week induction phase at weekly dosing, and it is company reported Phase 2 data on roughly 180 participants split across several dosing arms. It is a strong early signal, not an approved regimen.
What happens if someone just stops taking a GLP1 drug?
In this trial, the group that stopped active dosing entirely kept only 61% of the weight they had lost, versus up to 97% for every other week dosing and up to 90% for once monthly dosing. Stopping is not the same as spacing doses out further apart.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.